Atripla™ – HIV therapy in one pill
Boris Julg, Johannes R BognerMedizinische Poliklinik, Department of Infectious Diseases, University of Munich Medical School, Downtown Campus, GermanyAbstract: In July 2006 Atripla™ was approved by the US Food and Drug Administration (FDA), combining the active ingredients of one NNRTI and...
Saved in:
Main Authors: | Boris Julg (Author), Johannes R Bogner (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2008-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel immunological strategies for HIV-1 eradication
by: B. Jülg, et al.
Published: (2015) -
Pills, Pills, and More Pills: A Pill Box Exercise to Teach Barriers to Medication Adherence and Solutions
by: Kathryn Denson, et al.
Published: (2015) -
Availability in Spain of "one-pill killers" and other highly toxic drugs in infants
by: Lidia Martínez-Sánchez, et al.
Published: (2020) -
Combating HIV resistance – focus on darunavir
by: Cécile L Tremblay
Published: (2008) -
The Prostate Is Not a Pill and Therefore Has No Capsule
by: Johannes Kläger, et al.
Published: (2023)